Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

Fact checked by Jennifer Klump Although respiratory syncytial virus (RSV) is often associated with children, adults can also get it. RSV usually causes mild, cold-like symptoms such as cough, ...

GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage pipeline assets.

In July, the FDA agreed to review the application to extend the indication of Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) to adults aged 18-49 who are at increased risk.

GSK's Q2 results show that sales of its specialist oncology assets have risen by 42%, while general drug sales were down 6%.

MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline milestones.

The FDA has extended the review period for elinzanetant for the treatment of moderate to severe vasomotor symptoms due to menopause.

GSK is taking to the airwaves to talk RSV, presenting a TV special about how the pathogen has affected athletes in the upcoming National Senior Games.

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, highlighting the need for targeted outreach programs.

The FDA approved both RSVPreF3 (Arexvy; GSK) and RSVpreF (Abrysvo; Pfizer) in May 2023. 2,3 A year later, the FDA approved the mRNA-1345 (mRESVIA; Moderna) vaccine for RSV for adults 60 years and ...